Skip to main content
SpringerLink
Log in

Hypertension and Atherosclerosis: Pathophysiology, Mechanisms and Benefits of BP Control

  • Chapter
  • First Online:
Hypertension and Cardiovascular Disease

Abstract

Hypertension is a leading identifiable and reversible risk factor for myocardial infarction, heart failure, atrial fibrillation, aortic dissection, peripheral arterial disease, stroke and kidney failure [1, 2].. Hypertension is ranked first worldwide in an analysis of all risk factors for global disease burden in 2010 [2]. By the year 2025, hypertension is expected to increase in prevalence worldwide by 60 % and will affect 1.56 billion people [3]. Developing nations will experience an increase in the prevalence of hypertension by 80 % (from 639 million to 1.15 billion afflicted persons). As emerging countries have improved sanitation and other basic public health measures, cardiovascular (CV) disease has or soon will become the most common cause of death, and hypertension will be its most common reversible risk factor, as it already is in the United States.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mozaffarian D, Benjamin EJ, Go AS, et al. Executive summary: heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:434–41.

    Article  Google Scholar 

  2. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.

    Article  PubMed  Google Scholar 

  4. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869–74.

    Article  CAS  PubMed  Google Scholar 

  5. Joffres M, Falaschetti E, Gillespie C, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013;3:e003423.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.

    Article  PubMed  Google Scholar 

  7. Parati G, Ochoa JE, Bilo G, Agarwal R, Covic A, Dekker FW, Fliser D, Heine GH, Jager KJ, Gargani L, Kanbay M, Mallamaci F, Massy Z, Ortiz A, Picano E, Rossignol P, Sarafidis P, Sicari R, Vanholder R, Wiecek A, London G. Hypertension in chronic kidney disease part 1: out-of-office blood pressure monitoring: methods, thresholds, and patterns. Hypertension. 2016;67(6):1093–101. doi:10.1161/HYPERTENSIONAHA.115.06895.

    Article  CAS  PubMed  Google Scholar 

  8. Quinn U, Tomlinson LA, Cockcroft JR. Arterial stiffness. JRSM Cardiovasc Dis. 2012;1:cvd.2012.012024.

    PubMed  PubMed Central  Google Scholar 

  9. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932–43.

    Article  CAS  PubMed  Google Scholar 

  10. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63:636–46.

    Article  PubMed  Google Scholar 

  11. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: A clinical review. J Hypertens. 2006;24:983.

    Article  CAS  PubMed  Google Scholar 

  12. Spieker LE, Flammer AJ, Luscher TF. The vascular endothelium in hypertension. Handb Exp Pharmacol. 2006;249–283.

    Google Scholar 

  13. Dharmashankar K, Widlansky ME. Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep. 2010;12:448–55.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Taddei S, Virdis A, Mattei P, et al. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol. 1992;20 Suppl 12:S193–5.

    Article  PubMed  Google Scholar 

  15. Popolo A, Autore G, Pinto A, et al. Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radic Res. 2013;47:346–56.

    Article  CAS  PubMed  Google Scholar 

  16. Quyyumi AA, Patel RS. Endothelial dysfunction and hypertension: cause or effect? Hypertension. 2010;55:1092–4.

    Article  CAS  PubMed  Google Scholar 

  17. Shimbo D, Muntner P, Mann D, et al. Endothelial dysfunction and the risk of hypertension: the multi-ethnic study of atherosclerosis. Hypertension. 2010;55:1210–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Rosendahl A, Niemann G, Lange S, et al. Increased expression of (pro)renin receptor does not cause hypertension or cardiac and renal fibrosis in mice. Lab Invest. 2014;94:863–72.

    Article  CAS  PubMed  Google Scholar 

  19. Peixoto AJ, Orias M. Is there a role for direct renin inhibitors in chronic kidney disease? Curr Opin Nephrol Hypertens. 2009;18:397–403.

    Article  CAS  PubMed  Google Scholar 

  20. Acelajado MC. Pathogenesis of hypertension. In: Black HR, Elliott W, editors. Hypertension: a companion to Braunwald’s heart disease. Philadelphia: Elsevier; 2013.

    Google Scholar 

  21. Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006;103:17985–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. xxx

    Google Scholar 

  23. Crowley SD, Gurley SB, Oliverio MI, et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest. 2005;115:1092–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol. 2012;350:256–65.

    Article  CAS  PubMed  Google Scholar 

  25. Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens. 2011;20:62–8.

    Article  CAS  PubMed  Google Scholar 

  26. Ferrario CM. ACE2: more of Ang-(1–7) or less Ang II? Curr Opin Nephrol Hypertens. 2011;20:1–6.

    Article  CAS  PubMed  Google Scholar 

  27. Fraga-Silva RA, Costa-Fraga FP, Murca TM, et al. Angiotensinconverting enzyme 2 activation improves endothelial function. Hypertension. 2013;61:1233–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al. Structurebased identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51:1312–7.

    Article  CAS  PubMed  Google Scholar 

  29. Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2010;55:90–8.

    Article  CAS  PubMed  Google Scholar 

  30. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114:1804–14.

    Article  CAS  PubMed  Google Scholar 

  31. DiBona GF. Sympathetic nervous system and hypertension. Hypertension. 2013;61:556–60.

    Article  CAS  PubMed  Google Scholar 

  32. Grassi G, Cattaneo BM, Seravalle G, et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68–72.

    Article  CAS  PubMed  Google Scholar 

  33. Smith PA, Graham LN, Mackintosh AF, et al. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens. 2004;17:217–22.

    Article  PubMed  Google Scholar 

  34. Mu S, Shimosawa T, Ogura S, et al. Epigenetic modulation of the renal beta-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med. 2011;17:573–80.

    Article  CAS  PubMed  Google Scholar 

  35. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354–9.

    Article  CAS  PubMed  Google Scholar 

  36. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blockerinduced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52:1482–9.

    Article  CAS  PubMed  Google Scholar 

  37. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685–92.

    Article  PubMed  Google Scholar 

  38. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358:1370.

    Article  CAS  PubMed  Google Scholar 

  39. Gradman AH, Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis. 2006;48:326.

    Article  PubMed  Google Scholar 

  40. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52.

    Article  CAS  PubMed  Google Scholar 

  41. Nwankwo T, Yoon SS, Burt V, et al. Hypertension among adults in the United States: national health and nutrition examination survey, 2011–2012. NCHS Data Brief. 2013;133:1–8.

    PubMed  Google Scholar 

  42. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959–68.

    Article  CAS  PubMed  Google Scholar 

  43. Falaschetti E, Mindell J, Knott C, et al. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet. 2014;383:1912–9.

    Article  PubMed  Google Scholar 

  44. Sundstrom J, Arima H, Woodward M, et al. Blood pressure– lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591–8.

    Article  PubMed  Google Scholar 

  45. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603–15.

    Article  PubMed  Google Scholar 

  46. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121–3.

    Article  CAS  PubMed  Google Scholar 

  47. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578.

    Article  CAS  PubMed  Google Scholar 

  48. Wright Jr JT, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103.

    Article  CAS  PubMed  Google Scholar 

  49. Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575.

    Article  PubMed  Google Scholar 

  50. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145.

    Article  CAS  PubMed  Google Scholar 

  51. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782.

    Article  CAS  PubMed  Google Scholar 

  52. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217.

    Article  CAS  PubMed  Google Scholar 

  53. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058.

    Article  CAS  PubMed  Google Scholar 

  54. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174.

    Article  Google Scholar 

  55. NAVIGATOR Study Group, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477.

    Article  Google Scholar 

  56. Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med. 2009;151:861.

    Article  PubMed  Google Scholar 

  57. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011;305:913.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. D’Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ. 1991;303:385.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884.

    Article  PubMed  Google Scholar 

  60. Boutitie F, Gueyffier F, Pocock S, et al. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med. 2002;136:438.

    Article  PubMed  Google Scholar 

  61. Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31:2897.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Georgetown University, Washington, DC, USA

    Misbah Zaheer M.D. & Vasilios Papademetriou M.D.

  2. Department of Veterans Affairs Medical Center, and National Institutes of Health (NIH), Intramural Research Program (IRP), Institute of Clinical Research, Washington, DC, USA

    Paola Chrysostomou

  3. Division of Hypertension and Vascular Medicine, Veteran Affairs Medical Center, Washington, DC, USA

    Vasilios Papademetriou M.D.

Authors
  1. Misbah Zaheer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Chrysostomou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vasilios Papademetriou M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vasilios Papademetriou M.D. .

Editor information

Editors and Affiliations

  1. Fourth Internal Medicine Department, Evangelismos State General Hospital, Athens, Greece

    Emmanuel A. Andreadis

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Zaheer, M., Chrysostomou, P., Papademetriou, V. (2016). Hypertension and Atherosclerosis: Pathophysiology, Mechanisms and Benefits of BP Control. In: Andreadis, E. (eds) Hypertension and Cardiovascular Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-39599-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-39599-9_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-39597-5

  • Online ISBN: 978-3-319-39599-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation